1. Friedman Z, Neumann E, Hyams SW, Peleg B. Ophthalmic screening of 38,000 children, age 1 to 2 1/2 years, in childwelfare clinics. J Pediatr Ophthalmol Strabismus. 1980; 17:261–7.
2. Simons K. Preschool vision screening: rationale, methodology and outcome. Surv Ophthalmol. 1996; 41:3–30.
Article
3. Vereecken EP, Brabant P. Prognosis for vision in amblyopia after the loss of the good eye. Arch Ophthalmol. 1984; 102:220–4.
Article
4. Kaye SB, Chen SI, Price G, et al. Combined optical and atropine penalization for the treatment of strabismic and anisometropic amblyopia. J AAPOS. 2002; 6:289–93.
Article
5. Kaye SB, Chen SI, price G, et al. Combined optical and atropine penalization for the treatment of strabismic and anisometropic amblyopia. J AAPOS. 2002; 6:289–93.
Article
6. Searle A, Norman P, Harrad R, Vedhara K. Psychosocial and clinical determinants of compliance with occlusion therapy for amblyopic children. Eye (Lond). 2002; 16:150–5.
Article
7. Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of children treated for amblyopia. Eye (Lond). 1994; 8:627–31.
Article
8. Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus. 1999; 36:19–24.
Article
9. Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. Ophthalmology. 1997; 104:2156–60.
Article
10. Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for moderate amblyopia in children. Ophthalmology. 2004; 111:2076–85.
11. Foley-Nolan A, McCann A, O'keefe M. Atropine penalization versus occlusion as the primary treatment for amblyopia. Br J Ophthalmol. 1997; 81:54–7.
12. Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology. 1993; 100:323–7.
Article
13. Marron J. Cycloplegia and mydriasis by use of atropine, scopol-amine and homatropine-paredrine. Arch Ophthalmol. 1940; 23:340–50.
Article
14. Miranda MN. Residual accomodation. A comparison between cyclopentolate 1% and a combination of cyclopentolate 1% and tropi-camide 1%. Arch Ophthalmol. 1972; 87:515–7.
15. Zetterström C. A cross-over study of cycloplegic effects of a single topical application of cyclopentolate-phenylephrine and routine atropinisation for 3.5 days. Acta Ophthalmol. 1985; 63:525–9.
16. Milder B, Riffenburgh RS. An evaluation of cyclogyl (compound 75 GT). Am J Ophthalmol. 1953; 36:1724–6.
Article
17. Priestley B, Medine MM. New mydriatic and cycloplegic drug. Am J Ophthalmol. 1951; 34:638–9.
18. Campbell FW, Gregory AH. Effect of size of pupil on visual acuity. Nature. 1960; 187:1121–3.
Article
19. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthalmol. 2002; 120:268–78.
20. Scott WE, Dickey CF. Stability of visual acuity in amblyopic patients after visual maturity. Graefes Arch Clin Exp Ophthalmol. 1988; 226:154–7.
Article
21. Park SH, Yoon IN, Rah SH. The effect of atropinization of refractive accommodative esotropia patients with amblyopia. J Korean Ophthalmol Soc. 2003; 44:2292–8.
22. Ahn HB, Yoo KW, Rho SH. The cycloplegic effect of atropine. J Korean Ophthalmol Soc. 1995; 36:2029–34.
23. Flynn JT, Schiffman J, Feuer W, Corona A. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc. 1998; 96:431–50.
24. Park SC, Lee KH, Lee JR. Clinical approach for visual achievement in amblyopia treatment. J Korean Ophthalmol Soc. 1991; 32:802–8.